Liver Transplantation and Uveal Malignant Melanoma

Open Non-randomized Study to Assess the Benefit of Liver Transplantation in Patients With Liver Metastasis After Ocular Malignant Melanoma (Uveal Melanoma)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01311466

Enrollment

Registered

2011-03-09

Start date

2011-01-31

Completion date

2015-10-31

Last updated

2017-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveal Malignant Melanoma

Keywords

Liver transplantation, Overall survival

Brief summary

Patients with uveal malignant melanoma with liver metastases have median survival of less than 12 months. There is no established treatment showing increased overall survival. The study will determine if liver transplantation will result in long term survival in patients with liver metastases from uveal malignant melanoma.

Interventions

PROCEDURELiver transplantation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Uveal malignant melanoma * Liver metastases * ECOG 0-1

Exclusion criteria

* Extra hepatic disease * Previous other malignancy * Previous organ transplantation

Design outcomes

Primary

Measure	Time frame	Description
Over all survival	1 year	Patient survival after livertransplantation

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026